Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
IGF-1 DES67 residuesTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: des(1-3)IGF-1, des-IGF-1, IGF-1 DES(1-3)
Ten times the potency of native IGF-1, cleared from circulation in under 30 minutes. IGF-1 DES (des(1-3) Insulin-like Growth Factor-1) is a 67-amino-acid truncated analog that bypasses all six IGF binding proteins. That bypass is the entire point. Without binding protein sequestration, every microgram reaches the receptor in free form. The trade-off is a half-life so short it demands intramuscular injection within minutes of finishing a set. Bodybuilders and advanced peptide users prize it for one thing no other compound replicates: site-specific muscle growth in the exact muscle group just trained.
Sixty-seven amino acids. Three fewer than native IGF-1, and those three missing residues change everything. IGF-1 DES, also called des(1-3)IGF-1, drops the N-terminal tripeptide Gly-Pro-Glu that native IGF-1 uses to latch onto IGF binding proteins. The result: zero sequestration. Where native IGF-1 circulates 95 to 98 percent bound and biologically silent, the DES variant stays 100 percent free and active. Francis and colleagues confirmed the roughly 10-fold potency increase and a serum half-life around 27 minutes back in 1988 [1]. Ballard's group later mapped the full structural and binding profile [2]. Once it hits the IGF-1 receptor, the downstream signaling splits two ways. PI3K/Akt/mTOR drives protein synthesis. MAPK/ERK drives satellite cell proliferation, the pathway behind true muscle hyperplasia rather than just making existing fibers bigger. That satellite cell activation is what separates DES from conventional anabolics in the community conversation. Practical use centers on one protocol: intramuscular injection into the target muscle within 10 to 15 minutes of finishing training. The short half-life means systemic exposure stays low while local receptor saturation stays high. Community reports across r/Peptides and r/steroids describe measurable localized size increases by weeks 3 to 4, with 50 to 100 mcg per muscle group being the most common dose range. No human clinical trials exist for this specific application. All efficacy data for site-specific hypertrophy comes from animal models and community experience.
The first three amino acids of native IGF-1 (Gly-Pro-Glu) form the primary recognition site for all six IGF binding proteins. Remove them and the molecule can no longer be captured. That single structural change is why IGF-1 DES reaches the receptor at full concentration while native IGF-1 circulates mostly in a bound, inactive state. Receptor binding triggers autophosphorylation of the IGF-1 receptor (IGF-1R), which recruits IRS-1 (insulin receptor substrate-1). From there, signaling branches. The PI3K/Akt/mTOR arm phosphorylates p70S6K and 4E-BP1 to increase translation of muscle-specific mRNAs; this is direct protein synthesis stimulation. The MAPK/ERK arm activates satellite cell proliferation, the process behind muscle hyperplasia. New fiber formation, not just bigger existing fibers. Because the half-life sits around 20 to 30 minutes, the anabolic signal is intense but brief. Tissue exposed to the injection gets saturated. Distant organs and tissues see minimal IGF-1R activation. That pharmacokinetic profile is why intramuscular delivery post-workout is standard; subcutaneous or systemic dosing wastes the compound to plasma clearance before it can concentrate at any target site.
Well-established pharmacology: IGFBP non-binding confirmed, ~10x potency vs native IGF-1 confirmed [2], half-life ~25 min confirmed [1]. Zero human clinical trials for site-specific muscle hypertrophy. Evidence base is preclinical only.
Francis GL et al. 1988: IGFBP non-binding mutants with ~27 min half-life, ~10x potency (PMID 2454805); Ballard FJ et al. 1996: des(1-3)IGF-I structure and binding properties (PMID 8930132)
No human RCTs or PK studies. No formal dose-response data in humans. All in vivo data from rodent models (gut resection, growth studies). No safety data beyond acute animal toxicology.
Valued specifically for site-specific IM dosing post-workout. Considered an advanced tool for lagging body parts. Enthusiasm tempered by hypoglycemia risk and vendor quality concerns.
Scientific mechanism (IGFBP bypass → local receptor saturation → MAPK/ERK-driven hyperplasia) is well-established and explains the community use case. However, human clinical data is absent: site-specific anabolic efficacy in healthy athletes is inferred, not proven. Community dose ranges (40–120 mcg IM) are extrapolated from animal data with no formal PK bridge.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Training days only (4-5x/week) |
| Moderate | 80mcg | Training days only (4-5x/week) |
| Aggressive | 120mcg | Training days only (4-5x/week) |
Reconstitution math for the two common vial sizes. For a 0.1 mg (100 mcg) vial: add 1 mL bacteriostatic water. Concentration becomes 100 mcg/mL. A 50 mcg dose is 50 units on a U-100 insulin syringe. For a 1 mg vial: add 2 mL bacteriostatic water. Concentration becomes 500 mcg/mL. A 50 mcg dose is 10 units; 80 mcg is 16 units; 100 mcg is 20 units on a U-100 syringe. Timing is everything with DES. You have a 10-to-15-minute window after finishing the target muscle group to get the injection done. Prep your syringe before your last working set so you're ready. The ultra-short half-life means delays past 15 minutes post-workout significantly reduce local receptor exposure. Vendor quality is a real concern. The research-chemical market for DES has documented purity inconsistencies. Get a Certificate of Analysis from Janoshik or Colmaric before committing to a vial. Start with a low test dose (20 to 30 mcg) to assess your blood glucose response before running a full protocol.
Short cycles of 4-6 weeks are standard due to potential IGF-1R desensitization with prolonged use. Some protocols use only on training days (3-5 days per week) to extend cycle duration while minimizing total exposure. Allow a full 4-week off period between cycles to restore receptor sensitivity.
Prolonged continuous IGF-1R agonism leads to receptor downregulation through internalization and reduced surface expression. The MAPK/ERK signaling response that drives satellite cell proliferation diminishes with sustained activation. Standard 4–6 week cycles are designed to stay within the window of peak receptor sensitivity.
Or use the universal Peptide Calculator for any peptide.
Expected: Measurable localized size increase in injected muscle groups by week 4. Gains in muscle density and fiber count (hyperplasia) should be more durable than hypertrophy alone.
Monitor: Check fasting and post-injection blood glucose during week 1. If symptomatic hypoglycemia occurs, reduce dose to 30–40 mcg and optimize carbohydrate protocol before re-escalating.
Reconstitute lyophilized powder by adding bacteriostatic water to the vial. For a 1 mg vial, use 2 mL. Aim the stream down the glass wall, not directly onto the powder. Swirl gently until dissolved.
For 50 mcg at 500 mcg/mL concentration, draw to the 10 unit mark. For 80 mcg, draw to 16 units. For 100 mcg, draw to 20 units.
Inject intramuscularly into the muscle group you just finished training. Do this within 10 to 15 minutes of completing your last set. For bilateral muscles (quads, biceps, delts), split the dose between left and right sides.
Immediately consume 20 to 50 grams of fast-acting carbohydrates. Dextrose powder, fruit juice, or glucose tablets all work. Do not skip this step.
Monitor for hypoglycemia symptoms (shakiness, lightheadedness, mental fog) for 30 to 45 minutes post-injection. Keep additional carbs nearby during this window.
Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 2 to 3 weeks. Discard if the solution turns cloudy or shows particulates.
Do not hit the same spot more than 2 to 3 times per week. A standard cycle runs 4 to 6 weeks on, followed by 4 weeks off.
Standard dose as listed; full local receptor exposure
The entire clinical rationale for DES is IM post-workout delivery. SubQ injection or systemic dosing eliminates the site-specific advantage and wastes compound to plasma clearance within 25–30 min.
Absorption occurs but local IM concentration in target muscle is not achieved; site-specific hyperplasia benefit is lost
May be used for injury recovery when the target tissue is superficial or SubQ injection can be placed close to the injury site. Some practitioners use SubQ for systemic IGF-1R effects at higher doses (100–150 mcg), though IGF-1 LR3 is better suited for systemic use.
Drives pulsatile GH release at bedtime, creating systemic anabolic environment that complements DES local effects. Most popular community pairing for hypertrophy.
CJC-1295 (no DAC) 100–200 mcg + Ipamorelin 200–300 mcg SubQ at bedtime; IGF-1 DES IM post-workout
Pairs with CJC-1295 (no DAC) for clean GH pulse stimulation without cortisol/prolactin spikes. Used at bedtime while IGF-1 DES is used post-workout.
See CJC-1295 entry above: typically dosed together
Combined for injury recovery stacks: BPC-157 provides angiogenesis and anti-inflammatory repair; DES provides local IGF-1R anabolic signaling.
BPC-157 250–500 mcg SubQ or IM near injury + IGF-1 DES 50 mcg IM near injury
Added to injury stacks for systemic actin-binding and tissue migration effects. Complements the localized action of DES.
Both insulin and IGF-1 DES drive glucose uptake via overlapping receptor pathways. Combination creates extreme and unpredictable hypoglycemia risk: cited as the single most dangerous combination in community harm-reduction literature.
Do not combineCombining short-acting DES with long-acting LR3 creates layered IGF-1 receptor saturation and prolonged hypoglycemia risk. Community consensus: use one or the other, not both concurrently.
Do not combineAdditive blood glucose lowering with IGF-1 DES increases hypoglycemia risk significantly.
Both affect glucose homeostasis. Combined use increases hypoglycemia risk and may amplify GI side effects.
Pricing updated 2026-04-09
Hypoglycemia is the primary acute risk and the side effect that demands the most attention. IGF-1 DES activates insulin-like glucose uptake through IGF-1R and insulin receptor cross-activation in skeletal muscle. Blood sugar can drop fast, especially at doses above 50 to 80 mcg systemic. Users who skip post-injection carbohydrates report lightheadedness, shakiness, and cognitive fog within 15 to 30 minutes of injection. Keep glucose tablets or fast-acting carbs (dextrose, fruit juice) within arm's reach. Always eat 20 to 50 grams of carbohydrates within 15 minutes of injecting. Never inject on an empty stomach. The risk is highest during weeks 1 and 2 while you're still calibrating your personal dose threshold. Injection site reactions are common. Redness, swelling, and soreness at the intramuscular injection point appear frequently, particularly when the same site gets repeated hits. Do not inject into the same location more than 2 to 3 times per week. Chronic injection at one site raises a theoretical risk of localized tissue overgrowth. Water retention and joint discomfort show up at higher doses. Some users report puffiness around injection sites and stiff joints during weeks 2 to 4 at doses above 80 mcg. These typically resolve when dose is reduced or the cycle ends. Headaches and brain fog are reported but usually trace back to glucose fluctuations rather than a direct peptide effect. A finger-stick blood glucose reading will clarify the cause. Cancer risk deserves direct acknowledgment. IGF-1R activation promotes cell proliferation. A Lancet meta-analysis of 12 prospective studies [3] found associations between raised circulating IGF-1 and increased cancer risk (prostate, colorectal, premenopausal breast). Anyone with active malignancy, a personal cancer history, or raised baseline IGF-1 should not use this compound. There is no ambiguity on this point. No human clinical trials have evaluated IGF-1 DES safety at the doses used in the community. All safety data comes from animal models and user reports. Pregnancy and breastfeeding are absolute contraindications; no reproductive safety data exists. When to stop: persistent symptomatic hypoglycemia despite carb loading, unusual localized swelling or tissue changes at injection sites, any new cancer diagnosis.
Verify IGF-1 DES dosing and safety with a second opinion
Research-chemical market only. No compounding pharmacy pathway; not on RFK/HHS 2026 reclassification list. Vendor purity highly variable: community consistently documents inconsistent HPLC results across suppliers. Mislabeling with native IGF-1 or LR3 is possible.
| Test | When | Target |
|---|---|---|
| Blood glucose (finger-stick) | Before injection and 30–45 min post-injection during week 1; ongoing if using doses >80 mcg | Pre-injection: >90 mg/dL; post-injection nadir: >70 mg/dL |
| Serum IGF-1 | Baseline before cycle; optional at cycle midpoint (week 3) | Age-appropriate normal range; flag if >300 ng/mL at baseline |
| Fasting insulin | Baseline recommended; especially if stacking with GH secretagogues or using >80 mcg | — |
| Local tissue inspection | Each injection session | — |
IGF-1 DES drives skeletal muscle glucose uptake via IGF-1R/insulin receptor cross-activation; unmanaged hypoglycemia is the primary acute risk
Elevated baseline IGF-1 (acromegaly, pre-existing GH axis dysfunction) substantially increases risk of adverse effects
IGF-1 DES has insulin-like activity; baseline metabolic status informs safe dose ceiling
Chronic injection into the same site raises theoretical localized tissue overgrowth risk; rotate injection points and monitor for unusual swelling
Initial blood glucose fluctuations may occur. Mild pump sensation in injected muscles reported within the first session. Injection site soreness or redness possible. Establish post-workout timing and blood sugar management routine.
Increased muscle fullness and pumps in injected muscle groups during and after training. Temporary water retention around injection sites. Appetite changes and mild hypoglycemia episodes if carb intake is not managed.
Measurable improvements in injected muscle group size and recovery speed. Localized growth effects become visible in trained and injected areas. Peak response window for satellite cell activation and new fiber formation.
Continued but potentially diminishing returns as IGF-1R sensitivity decreases. Cycle off after 4-6 weeks. Gains in muscle density and localized size should be retained with consistent training through the off period.
Days 1 to 3 (Calibration phase): Blood glucose is the main variable during these first sessions. IGF-1R activation drives acute glucose uptake in the injected muscle. Most users notice a localized pump effect during the workout itself. Mild lightheadedness or shakiness happens if the post-injection carb load is insufficient. Injection site soreness is common. The goal here is dialing in your carbohydrate timing and dose threshold, not chasing growth. Weeks 1 to 2 (Pump and fullness onset): Satellite cell proliferation begins at the molecular level, though nothing structural has changed yet. What you will notice is increased fullness and vascularity in injected muscle groups during and between workouts. Water retention around injection sites is normal. Appetite changes are common. Joint stiffness or swelling can appear at doses above 80 mcg. Glucose fluctuations should be more predictable by now if your carb protocol is consistent. Weeks 3 to 4 (Peak response window): This is when the community says the real results show up. Satellite cell activation and differentiation hit their maximum window based on animal model data. Measurable size increases in injected muscle groups become visible. Recovery speed improves noticeably. Some users report response beginning to plateau toward the end of week 4, which may signal early receptor desensitization. Weeks 5 to 6 (Extended cycle and diminishing returns): IGF-1R downregulation is expected with prolonged agonist exposure. The response is clearly tapering. Most experienced users cycle off between weeks 4 and 6. Gains should retain well with continued training through the off period. The reduced efficacy itself is the signal to stop; pushing past it produces minimal benefit with ongoing risk.
IGF-1R activation drives acute glucose uptake in injected muscle tissue. Satellite cell signaling begins via MAPK/ERK pathway.
Noticeable muscle pump in injected area during workout. Some report mild blood glucose dips (lightheadedness) if carb loading is insufficient.
Satellite cell proliferation begins. Local protein synthesis upregulated via PI3K/Akt/mTOR. No visible structural changes yet.
Increased fullness and vascularity in injected muscle groups. Water retention around injection sites. Appetite changes common.
Maximum satellite cell activation and differentiation window. New myofiber formation (hyperplasia) hypothesized at this stage based on animal model data.
Measurable size increases in injected muscle groups. Recovery speed notably improved. This is the window most users describe as the "real gains" phase.
IGF-1R downregulation expected with prolonged agonist exposure; receptor sensitivity diminishes.
Response clearly diminishing. Most community members cycle off at week 4–6. Gains retain well with continued training during off period.
Source: Estimated 20-30 min based on near-zero IGFBP affinity vs native IGF-1 (bound t½ ~12-15h, free t½ ~10 min); Francis et al. 1988 PMID 2454805, Ballard et al. 1996 PMID 8930132
Loading the interactive decay curve.
IGF-1 DES is classified as a research chemical. It has no FDA approval for any indication and is not available through compounding pharmacies. Purchase and possession for personal research is legal in most jurisdictions, but it cannot be marketed for human consumption. The compound is sold by research peptide vendors under "not for human use" labeling. WADA (World Anti-Doping Agency) prohibits all forms of IGF-1 and IGF-1 analogs in competition and out of competition. Athletes subject to drug testing should assume detection is possible; IGF-1 DES falls squarely under the prohibited growth factor category. No pending regulatory changes affect IGF-1 DES specifically. It is not included in the 2026 RFK/HHS reclassification proposals that cover certain compounded peptides. Its status as a research-only compound is unlikely to change in the near term given the absence of any sponsor pursuing clinical development. This content is for educational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any research compound.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
